![]() |
|
|
School of Human Science and Environment, Himeji Institute of Technology, University of Hyogo, Himeji, 6700092, Japan and * Byotai Seiri Laboratory, Tokyo, 1730025, Japan
2To whom correspondence should be addressed. E-mail: watanabe{at}shse.u-hyogo.ac.jp.
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: 3-hydroxyisovaleric acid HPLC biotin deficiency methylcrotonyl CoA carboxylase urine
Biotin is a cofactor for several carboxylases used in fatty acid synthesis, gluconeogenesis, and BCAA metabolism. The major biotin-containing enzymes are ß-methylcrotonyl-CoA carboxylase (MCC),3 propionyl-CoA carboxylase, pyruvate carboxylase, and acetyl CoA carboxylase. MCC catalyzes an essential step in the degradation of leucine, which converts ß-methylcrotonyl-CoA to 3-methylglutaconyl-CoA. The reduced activity of MCC leads to an elevated excretion of 3-methylcrotonic acid, the product of its hydration (3-hydroxyisovaleric acid: 3-HIA), and 3-methylcrotonylglycine, formed by conjugation with glycine. The increased urinary excretion of these abnormal metabolites reflects reduced activity of MCC or is due to dietary biotin depletion in genetically normal individuals.
Conditions that cause biotin deficiency include the following: long-term consumption of undenatured egg white; infant diets that do not include biotin; deficiency of one or more of the biotin-dependent carboxylases in inherited metabolic disorders; biotinidase deficiency and holocarboxylase synthetase deficiency; and biotin transporter deficiency (1,2). One of the most important criteria for the diagnosis of biotin deficiency is the detection of organic acids in urine, such as 3-HIA and 3-hydroxypropionic acid, which are elevated in biotin deficiency (35).
In general, 3-HIA in the urine and/or serum of biotin-deficient patients and experimental animals has been assayed by GC/MS, which is specific for assaying 3-HIA in screening tests for biotin deficiency. However, the procedure is complex and difficult. Therefore, we devised an assay for urinary 3-HIA by HPLC, using equipment that is available in most laboratories. We also discuss the usefulness of this method for assaying 3-HIA in the urine of biotin-deficient and biotin-supplemented mice and human infants.
| MATERIALS AND METHODS |
|---|
|
|
|---|
The mice consumed a biotin-deficient or biotin-supplemented diet ad libitum and had free access to distilled water for 6 wk. The body weights of the 14-wk-old mice were 27.9 ± 2.5 and 28.2 ± 2.0 g in the biotin-deficient and biotin-supplemented groups, respectively. Consumption of the diet was also confirmed to be approximately the same in both diet groups, as shown in our previous study (6). Urine was collected from 3 mice fed the biotin-deficient or biotin-supplemented diet every week for 6 wk. The urine of the mice in the individual metabolic cages was collected for 24 h and stored at 40°C until use. All procedures were performed in accordance with the standards related to the care and management of experimental animals of the Japanese Prime Ministers Office (7).
Urine collection in an infant. Because biotin is not yet registered in Japan as a food additive, except in some foods such as dietary supplements, it cannot be added to infant formulas. We demonstrated previously that the biotin concentration of special formulas for medical treatment and prevention of disease in Japan was less than a fifth of the level in American products (8). Therefore, it has often been reported that biotin deficiency develops in infants with food allergies or inborn errors of metabolism who have been fed special Japanese formulas (9).
In the present case, the infant studied was a 5-mo-old Japanese male. At 4 wks of age, he was diagnosed as having dyspepsia and started to receive maternal milk and/or special formula called Elemental Formula (Meiji Milk Products). Afterwards, prominent erythematous skin lesions developed on his eyelids, perioral region, and neck. Dietary biotin deficiency was strongly suspected and oral treatment with 1 mg/d biotin was started. After 2 wk, the skin lesions disappeared rapidly, and the infant recovered and remained well. Urine was collected 1 wk before and after the biotin treatment. This study was performed in accordance with the ethical principles for medical research involving human subjects (Declaration of Helsinki, World Medical Association). Informed consent was obtained from the parents at enrollment.
Reagents. For the HPLC analysis of standards, 3-HIA was obtained from Tokyo Kasei Kogyo. A kit (X8RFAR 01) for the analysis of short- and long-chain FFA by HPLC (YMC) was used for the pretreatment of the 3-HIA standard solution and urine samples. This kit contains a derivatized reagent that converts the carboxyl moiety of FFA into 2-nitrophenylhydrazide (2-NPH). Sensitive detection in the UV-visible range thus becomes possible after a simple derivatization procedure. Analytical reagent-grade acetonitrile was obtained from Wako Chemical Industries. The control urine "AUTION CHECK II," which is prepared from human urine and is used to monitor the precision of urinalysis, was obtained from Arkray.
Derivatization procedures. The derivatization procedure for fatty acids, including 3-HIA, was a modification of a previously reported technique (10,11) and was as follows:
Chromatographic analyses and conditions. Chromatographic separations were performed using a HITACHI HPLC system (Hitachi). The HPLC column was a C8 reversed-phase column for fatty acids (YMC-Pack FA), which was packed with Si 60 (particle size 5 µm, 250 x 4.6 mm) only for carboxylic acid.
The solvent system for elution from the YMC-Pack FA column consisted of acetonitrile:methyl alcohol:Milli-Q water (30:16:54, by vol). Solvents were adjusted to pH 4.5 with 0.01 mol/L HCl; they were filtered through a 0.45-µm membrane filter and degassed under decompression with ULVAC (Sinku Kiko). Separations were made at a flow rate of 1.0 mL/min. The column temperature was kept constant at 50°C. The elution patterns were monitored at 230 nm to detect the derivatized carbonyl moiety of 3-HIA. The retention time (RT, in min) on a YMC-Pack FA column ranged from 5 to 11 min.
Biochemical analyses. The biotin concentrations in the urine were quantified using a microtiter plate adaptation of the microbiological assay with Lactobacillus plantarum ATCC 8014. The microbioassay lacks specificity compared with biotin analysis using an HPLC/streptavidin assay. Urinary specimens were filtered through 0.45-µm membranes and assayed without hydrolysis. The creatinine concentrations were measured in all urine samples with the picric acid method using a Creatinine Test Wako kit (Wako Chemical Industries). The concentrations of urinary biotin and 3-HIA were expressed as µmol/mol creatinine and mmol/mol creatinine, respectively.
Statistical analyses. For statistical evaluation of the data in mice, repeated-measures ANOVA and Students t test were used. Differences of P < 0.05 were considered significant. StatView 5.01 (SAS Institute) software was used for all statistical analyses. Values in the text are means ± SD.
| RESULTS |
|---|
|
|
|---|
|
|
|
The chromatogram of urine obtained from the infant fed a special formula manufactured in Japan and suspected of being biotin deficient had its highest peak at 8.27 min(Fig. 1d). Another peak was detected at 8.77 min. However, these peaks were not detected in the urine after biotin treatment (Fig. 1e).
| DISCUSSION |
|---|
|
|
|---|
Several HPLC methods were developed for the analysis of fatty acids in serum and urine; these employ precolumn derivatization techniques to increase the sensitivity and specificity of detection (10,11,15,16). In the present study, the preprocessing, including labeling, was simplified by the use of the derivatization technique, and a method for 3-HIA measurement was established using a standard HPLC system. The lower limit of detection of urinary 3-HIA was 0.042 mmol/L. This sensitivity was sufficient to measure 3-HIA in urine samples from an infant suspected of being biotin deficient. A relatively higher peak of 3-HIA was obtained before biotin treatment compared with other fatty acids present in the urine. These findings suggest that this HPLC method is sufficiently sensitive for assaying urinary 3-HIA in screening tests for biotin deficiency in humans.
The recovery of 3-HIA was in the range of 90.1108.8%. This indicates that the present method does not have completely satisfactory precision for analyzing the 3-HIA concentration in urine because the method used here has several extraction and separation steps, which may affect the recovery of 3-HIA. The normal range of urinary 3-HIA in humans was reported to be from 5.1 to 10.7 mmol/mol creatinine as assessed by GC/MS, and it is increased several-fold by biotin deficiency (17). In the present study, the urinary 3-HIA concentration was 78.6 mmol/mol creatinine in an infant fed a special Japanese formula. However, no 3-HIA was detected after biotin treatment of this infant.
The concentrations of biotin and organic acids, and the activity of carboxylase in the serum and urine are generally used as indicators of biotin status (18,19). Mock et al. (35) demonstrated that decreased urinary biotin and increased urinary 3-HIA are sensitive indicators of early biotin deficiency, but methylcrotonylglycine and isovalerylglycine, which are also produced due to the decreased activity of MCC, are not. 3-HIA is detected in urine before the appearance of clinical signs of biotin deficiency; thus, it is expected to be a useful indicator of early biotin deficiency. The measurement of 3-HIA in urine may thus be useful for the diagnosis of biotin deficiency.
3-HIA is also a sensitive indicator of biotin deficiency in mice. 3-HIA was detected within a short time after the beginning of the feeding of a biotin-deficient diet, along with a decrease of biotin in the urine. Thus, the HPLC method for 3-HIA described here can be a useful tool clinically as well as in the research laboratory.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
3 Abbreviations used: 3-HIA, 3-hydroxyisovaleric acid; MCC, methylcrotonyl CoA carboxylase; 2-NPH, 2-nitrophenylhydrazide; RT, retention time. ![]()
Manuscript received 19 October 2004. Initial review completed 4 November 2004. Revision accepted 17 December 2004.
| LITERATURE CITED |
|---|
|
|
|---|
1. Mock, D. M., DeLorimer, A. A., Liebman, W. M., Sweetman, L. & Baker, H. (1981) Biotin deficiency: an unusual complication of parenteral alimentation. N. Engl. J. Med. 304:820-823.[Medline]
2. Wolf, B. & Feldman, G. L. (1982) The biotin-dependent carboxylase deficiencies. Am. J. Hum. Genet. 34:699-716.[Medline]
3. Mock, N. I., Malik, M. I., Stumbo, P. J., Bishop, W. P. & Mock, D. M. (1997) Increased urinary excretion of 3-hydroxyisovaleric acid and decreased urinary excretion of biotin are sensitive early indicators of decreased biotin status in experimental biotin deficiency. Am. J. Clin. Nutr. 65:951-958.
4. Mock, D. M., Henrich-Shell, C. L., Carnell, N., Stumbo, P. & Mock, N. I. (2004) 3-Hydroxypropionic acid and methylcitric acid are not reliable indicators of marginal biotin deficiency in humans. J. Nutr. 134:317-320.
5. Mock, D. M., Henrich, C. L., Carnell, N. & Mock, N. I. (2002) Indicators of marginal biotin deficiency and repletion in humans: validation of 3-hydroxyisovaleric acid excretion and a leucine challenge. Am. J. Clin. Nutr. 76:1061-1068.
6. Watanabe, T. (1983) Teratogenic effects of biotin deficiency in mice. J. Nutr. 113:574-581.
7. Japanese Prime Ministers Office (1980) The Standards Related to the Care and Management of Experimental Animals. Notification No. 6, March 27 1980.
8. Watanabe, T. & Fukui, T. (1998) Low biotin content of infant formulas made in Japan. Food Add. Contam. 15:619-625.
9. Higuchi, R., Noda, E., Koyama, Y., Shirai, T., Horino, A., Juri, T. & Koike, M. (1996) Biotin deficiency in an infant fed with amino acid formula and hypoallergenic rice. Acta Paediatr. 85:872-874.[Medline]
10. Miwa, H., Yamamoto, M., Nishida, T., Nunoi, K. & Kikuchi, M. (1987) High-performance liquid chromatographic analysis of serum long-chain fatty acids by direct derivatization method. J. Chromatogr. 416:237-245.[Medline]
11. Miwa, H. & Yamamoto, M. (1987) High-performance liquid chromatographic analysis of serum short-chain fatty acids by direct derivatization. J. Chromatogr. 421:33-41.[Medline]
12. Stokke, O., Eldjarn, L., Jellum, E., Pande, H. & Waaler, P. E. (1972) Beta-methylcrotonyl-CoA carboxylase deficiency: a new metabolic error in leucine degradation. Pediatrics 49:726-735.
13. Mock, D. M., Jackson, H., Lankford, G. L., Mock, N. I. & Weintraub, S. T. (1989) Quantification of urinary 3-hydroxyisovaleric acid using deuterated 3-hydroxyisovaleric acid as internal standard. Biomed. Environ. Mass Spectrom. 18:652-656.[Medline]
14. Teran-Garcia, M., Ibarra, I. & Velazquez, A. (1998) Urinary organic acids in infant malnutrition. Pediatr. Res. 44:386-391.[Medline]
15. DAmboise, M. & Gendreau, M. (1979) Isocratic separation of human blood plasma long chain free fatty acid derivatives by reversed phase liquid chromatography. Anal. Lett. 12:381-395.
16. Yamaguchi, M., Matsunaga, R., Hara, S., Nakamura, M. & Ohkura, Y. (1986) Highly sensitive determination of free fatty acids in human serum by high-performance liquid chromatography with fluorescence detection. J. Chromatogr. 375:27-35.[Medline]
17. Mock, D. M., Quirk, J. G. & Mock, N. I. (2002) Marginal biotin deficiency during normal pregnancy. Am. J. Clin. Nutr. 75:295-299.
18. Chastain, J. L., Bowers-Komro, D. M. & McCormick, D. B. (1985) High-performance liquid chromatography of biotin and analogues. J. Chromatogr. 330:153-158.[Medline]
19. Zempleni, J., McCormick, D. B. & Mock, D. M. (1997) Identification of biotin sulfone, bisnorbiotin methyl ketone, and tetranorbiotin-l-sulfoxide in human urine. Am. J. Clin. Nutr. 65:508-511.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||